Inmed pharmaceuticals signs non-binding letter of intent to acquire baymedica, a commercial manufacturer of rare cannabinoids

Vancouver, british columbia, june 29, 2021 (globe newswire) -- inmed pharmaceuticals inc. (“inmed” or the “company”) (nasdaq: inm), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids, announced that it has entered into a non-binding letter of intent (the "loi") to acquire baymedica inc. (“baymedica”), a private company based in nevada and california that specializes in the manufacture and commercialization of rare cannabinoids.
INM Ratings Summary
INM Quant Ranking